AMELIA ISLAND, Fla. — Reproxalap, an inhibitor to reactive aldehyde species, may be a critical tool in the future of treating a number of ocular inflammatory conditions, according to a presentation at Cataract Surgery: Telling It Like It Is.
“We learned about steroid inflammatory pathways in medical school, oncogenic acid, cyclooxygenase, lipoxygenase and all the great things that steroids do in such a multifactorial way,” John D. Sheppard, MD, president of Virginia Eye Consultants, said in his presentation. “It turns out, there are parallel inflammatory pathways that